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Abstract
Background: HIV-positive children in low-income settings face many challenges to adherence to antiretroviral treatment (ART)
and have increased mortality on treatment compared to children in developed countries. Adult ART programmes have
demonstrated benefit from community support to improve treatment outcomes; however, there are no empirical data on the
effectiveness of this intervention in children. This study compared clinical, virological and immunological outcomes between
children who received and who did not receive community-based adherence support from patient advocates (PAs) in four South
African provinces.
Methods: A multicentre cohort study of ART-naı ¨ve children was conducted at 47 public ART facilities. Outcome measures were
mortality, patient retention, virological suppression and CD4 percentage changes on ART. PAs are lay community health workers
who provide adherence and psychosocial support for children’s caregivers, and they undertake home visits to ascertain
household challenges potentially impacting on adherence in the child. Corrected mortality estimates were calculated, correcting
for deaths amongst those lost to follow-up (LTFU) using probability-weighted Kaplan-Meier and Cox functions.
Results: Three thousand five hundred and sixty three children were included with a median baseline age of 6.3 years and a
median baseline CD4 cell percentage of 12.0%. PA-supported children numbered 323 (9.1%). Baseline clinical status variables
were equivalent between the two groups. Amongst children LTFU, 38.7% were known to have died. Patient retention after
3 years of ART was 91.5% (95% CI: 86.8% to 94.7%) vs. 85.6% (95% CI: 83.3% to 87.6%) amongst children with and without PAs,
respectively (p 0.027). Amongst children aged below 2 years at baseline, retention after 3 years was 92.2% (95% CI: 76.7% to
97.6%) vs. 74.2% (95% CI: 65.4% to 81.0%) in children with and without PAs, respectively (p 0.053). Corrected mortality after
3 years of ART was 3.7% (95% CI: 1.9% to 7.4%) vs. 8.0% (95% CI: 6.5% to 9.8%) amongst children with and without PAs,
respectively (p 0.060). In multivariable analyses, children with PAs had reduced probabilities of both attrition and mortality,
adjusted hazard ratio (AHR) 0.57 (95% CI: 0.35 to 0.94) and 0.39 (95% CI: 0.15 to 1.04), respectively.
Conclusion: Community-based adherence support is an effective way to improve patient retention amongst children on ART.
Expanded implementation of this intervention should be considered in order to reach ART programmatic goals in low-income
settings as more children access treatment.
Keywords: antiretroviral treatment; children; community-based adherence support; outcomes; HIV; South Africa; low-income
settings.
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Introduction
Adherence to treatment is a challenge for patients with
chronic disease (with average adherence being 50% in
patients in developed countries) [1], and particularly for
adults on antiretroviral treatment (ART) in low- and middle-
income countries (LMIC), with patient retention being
as low as 60% after 2 years of treatment [2,3]. These
challenges are amplified in children in LMIC as parents are
often no longer alive and children need to depend on
relatives or others to access care and receive medication,
with the potential for poor adherence to prescribed regi-
mens. In addition, many paediatric ART formulations have
complex and strict dosage schedules needing constant
review as weight may increase over short periods of time.
Poor childhood cognitive skills, emotional distress, poverty,
food and shelter insecurity, non-disclosure, domestic vio-
lence, substance abuse along with geographic and com-
munity isolation all increase the difficulty of treatment
adherence [4]. Reviews have, nevertheless, indicated equal
or increased adherence amongst children in LMIC com-
pared to developed countries [5,6]. In contrast, children in
LMIC start ART with significantly more advanced disease
progression and have increased mortality on ART than
children in developed countries [5,7], and LMIC programme
attrition, particularly due to loss to follow-up (LTFU), is
substantial (17% after 2 years of ART) [8].
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1The South African Government expanded treatment access
in 2010 by including all HIV-positive children aged B1y e a r
as eligible for ART and by increasingly devolving paediatric
ART delivery to the primary healthcare (PHC) level and to
nursing staff [9].This places a greater burden on PHC services
as skills, capacity, infrastructure, as well as new strategies
are required to address the large treatment need [10]. In
addition, PHC personnel are often not confident about caring
for young HIV-positive infants [11]. In these circumstances,
psychosocial support and adherence counselling tend to be
neglected; hence, a need exists for lay community adherence
support programmes. Recently, there have been calls to
strengthen community-based support initiatives for patients
on ART [12,13]. Lay healthcare workers in primary and
community care have produced improved tuberculosis
(TB) treatment outcomes and reductions in morbidity and
mortality from childhood illnesses in non-ART settings
[1416]. Amongst adults receiving ART, social and commu-
nity support have been associated with improved adherence
and treatment outcomes [1720]. There is, however, little
or no data assessing the effectiveness of community-based
adherence-support programmes for children recieving ART.
Kheth’Impilo (KI) is a non-governmental organization
(NGO) in South Africa that has developed a community
adherence-support programme employing patient advocates
(PAs), who are lay community health workers providing
adherence and psychosocial support for patients on ART [18].
PAs provide education and support for children’s caregivers
during treatment preparation and initiation at the clinic, and
they undertake home visits to ascertain household challenges
potentially impacting on adherence in the child. These are
addressed at clinic multidisciplinary team (MDT) meetings
where solutions are presented and implemented. Regular
home visits continue after treatment initiation during which
caregivers are supported to ensure any ongoing challenges to
adherence are addressed.
The aim of this study was to evaluate the effectiveness
of an NGO-managed community-based support programme
amongst a multicentre cohort of children receiving ART in
South Africa, by comparing clinical, virological and immu-
nological outcomes between children who received and
who did not receive community-based adherence support
from PAs.
Methods
Study design and setting
A multicentre cohort study (with prospective data collection
and a retrospective definition of the study question) of
children enrolling for ART was conducted at 47 routine public
healthcare facilities supported by KI. All sites that had
electronic data collection systems were included in the
study. Facilities were distributed across four provinces
(Western Cape, KwaZulu-Natal, Eastern Cape and Mpuma-
langa), with 15 facilities being secondary level hospitals and
32 being PHC clinics. Seventeen sites had operational
community-based adherence-support programmes. All sites
treated both adults and children. All ART-naı ¨ve children
starting ART at these sites were eligible for this study.
Inclusion criteria
All ART-naı ¨ve children (B16 years of age) who enrolled for
triple combination ART between 1 January 2004 and 30
September 2009, who had their date of birth, gender and
date of starting ART documented, who were initiated on ART
at least 6 months before site database closure and who
had at least 1 day of follow-up time, and for whom it was
ascertained whether they received support from a PA or
not, were included in analyses.
Children were selected to start ART according to the
National Department of Health guidelines [21]. Briefly,
children with modified World Health Organization (WHO)
clinical Stage III or Stage IV disease, or a low CD4 cell
percentage irrespective of disease stage (B20% in children
under 18 months of age, or B15% if over 18 months old), or
recurrent or prolonged hospitalization were eligible for ART.
In addition, children were required to have an identifiable
adult caregiver who could administer the medication. First-
line ART consisted of two nucleoside reverse transcriptase
inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase
inhibitor (NNRTI) for those aged older than 3 years or a
protease inhibitor (PI) for those younger than 3 years.
Community-based support intervention
Patient advocates are community workers, chosen through as
transparent a process as possible with community represen-
tatives, clinic staff and NGO line managers involved in the
choice of appropriate candidates. They had completed high
school, were numerate and literate in English, were able to
speak the local language and had good community standing.
They were trained (for a 3 week intensive) on aspects of
adult and paediatric HIV and TB infection and treatment,
including psychosocial issues that impact on adherence and
how best to address these. PAs were remunerated by sub-
contracted NGOs prior to 2009, but have since been remu-
nerated directly by KI. The company cost per PA (January
2012) is USD 225 to 275 per PA per month. Each PA is as-
signed approximately 80 to 120 ART patients (adults and
children), with an approximate cost of USD 1.88 to 3.43 per
patient per month. The PA programme is funded by the
Global Fund to Fight AIDS, Tuberculosis and Malaria, US
Presidents Emergency Plan for AIDS Relief and the Western
Cape Department of Health. KI has a memorandum of under-
standing with each respective provincial health department.
During the treatment initiation phase, carers of children
were linked to a PA from the geographical area in which they
lived. As the community support programme for paediatric
ART patients was reasonably new, a relatively small propor-
tion of children at each site received PA support. Children
were eligible to be linked to a PA if a PA was active in the area
of the child’s home, PA capacity was available and if consent
was obtained from the carers. Clinical or socio-economic
criteria were not used to influence eligibility status.
During the initial home assessment, family and other
household members were evaluated together with the
patient. Issues assessed (using a standardized form) included
TB and HIV testing status of the household, nutrition
insecurity, substance abuse, domestic violence, non-disclo-
sure, social income grant access and documentation,
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2including birth and death certification. An assistant to the
home child-carer, such as a Treatment Buddy, was potentially
identified from the household or a close neighbour to further
support adherence. All psychosocial issues were discussed
at clinic MDT meetings (comprising doctors, nurses, clinic
adherence counsellors, PAs and social workers), and planned
interventions agreed by the MDT were implemented by the
PA, auxiliary social worker or social worker, depending on the
complexity of the issue.
Carers were also offered educational sessions, with topics
including HIV/TB information, the need for adherence to
medication, useful tips on nutrition, immunization schedules
and information about minor childhood illnesses and home
management of these, for example, preparation of oral
hydration solution for diarrhoeal disease.
Following the psychosocial screening visit, home visits
occurred weekly for a month. PAs supervised the taking of
medication and advised on problems that may have arisen.
The appropriate storage and hygiene of medicine utensils
was stressed. The frequency of subsequent visits remained
high, being at least monthly, as children were considered to
be very important patients, ‘VIP’. If clinic visits were delayed,
home visit frequency increased.
Patient assignment and outcome measures
Patients were assigned to the PA-supported group if
supported by a named KI patient advocate; else they were
assigned to the non-PA-supported group. An intention-
to-treat analysis was performed ignoring changes in assign-
ment status after treatment commenced. Outcome measures
were death, attrition, virological suppression and changes in
CD4 cell percentage on ART. Attrition was defined as a
combined endpoint of children dying or LTFU. LTFU was
defined as no clinic visit by a patient for 3 months
or more after the last scheduled appointment was missed.
This definition was used by clinic staff at the time and was
chosen to facilitate reasonably early tracing of non-atten-
dees. Children generally attended clinics monthly; visits were
spaced up to alternate monthly for certain older children
who were stable on treatment. Non-PA-supported children
who missed appointments would initially be traced by
telephone or, where available, a district tracing team would
visit the child’s house. Time was measured from the start of
ARTand ended at the earliest of the date of last clinic follow-
up visit (for patients dying, transferring out or LTFU), 36
months after starting ART, NGO exit from a site or 31 March
2010. The NGO exited from 10 sites during the study period,
which facilitated staff (including PAs, as applicable) to be
absorbed by the department of health. Follow-up data were
censored where the NGO exited from a site.
To ascertain deaths amongst patients LTFU, the vital status
of patients LTFU who had valid civil identification numbers
were cross-checked by comparing with national death
records. Data were compared anonymously. Cause of death
data were not available.
CD4 cell count and percentage were measured at ART
initiation and at 6-monthly intervals, and viral load was
monitored 6-monthly on treatment. The proportion of
children achieving virological suppression was measured
amongst children remaining in care and having available
viral load test results and was defined as a viral load B400
copies/ml. Severe immunodeficiency was defined according
to age-specific WHO criteria [22]. Laboratory monitoring was
performed by the National Health Laboratory Services using
the Panleucogating method (CD4 cell count) [23] and the
Nuclisens HIV1 QT assay (bioMerieux, Marcy-Etoile, France)
(viral load).
Data collection and statistical analyzes
Individual-level patient data were collected prospectively
for routine monitoring purposes by designated site-based
data capturers at each patient visit using custom-designed
databases, which were pooled on a quarterly basis to a
central data warehouse using standard operating procedures.
Continual data cleaning and quality control routines were
implemented to enhance data validity. Missing data values
were attempted to be retrieved by hand searching paper-
based patient records at facilities.
Baseline characteristics between groups were compared
using the Pearson’s x
2 and Wilcoxon rank-sum tests, as
appropriate. Kaplan-Meier estimates of time to death and
attrition after starting ART were calculated. To correct for
patients who were LTFU but had died, corrected mortality
estimates were derived using probability-weighted Kaplan-
Meier functions [24]. In this approach, the updated vital
status amongst patients who were LTFU at facility level for
whom a definitive outcome could be established from the
national death registry was used to represent outcomes
among all those LTFU. A probability weight (the ratio of all
patients LTFU to those LTFU with updated vital status) was
assigned to lost patients with sampling-updated vital status,
and other lost patients were dropped from the analysis. The
logrank test was used to compare groups.
Multivariable Cox proportional hazards regression was
used to assess group effect associated with death (based
on the weighted data) and attrition after starting ART,
adjusting for baseline patient variables (age, gender, WHO
clinical stage, immunological status, weight-for-age z (WAZ)-
score, year of starting ART, tuberculosis treatment, initial
regimen) and site-related variables (health system level,
province, rural/urban nature of site) as well as accounting
for unmeasured heterogeneity between site cohorts. Missing
baseline values were considered as separate categories
within variables [8], to retain observations in multivariable
models. All adjusted models included all baseline variables.
Three sets of multivariable sensitivity analyzes of mortality
and attrition were performed: I  ignoring death registry
information and assigning vital status based on site-level
ascertainment only; II  restricting outcome analyzes to
children enrolled at facilities at which the community-based
adherence programme was operational; and III  restricting
analyses to children enrolled at PHC facilities only (excluding
hospital-based clinics). Statistical analyses were performed
using Stata versions 9.1 and 11.1 (Stata Corporation, College
Station, TX, USA). The study was approved by the University
of Cape Town Research Ethics committee.
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3Results
Database records for a total of 6442 children younger than
16 years of age were screened for eligibility for the study.
Children excluded were 1134 who commenced ART within
6 months of closure of the site database, 1381 who were
documented as being ART experienced, 269 who had 0 days
of follow-up time and 95 for whom it could not be
definitively ascertained as to whether they received sup-
port from a PA or not. Thus, 3563 ART-naı ¨ve children were
included in analyzes.
There were 323 (9.1%) and 3240 (90.9%) children who
received and did not receive support from a PA, respectively
(Table 1). At the start of treatment, PA-supported children
had a higher proportion aged below 1 year, a higher
proportion treated at PHC facilities, a lower proportion
who were treated at rural facilities, lower proportions
from Mpumalanga and Eastern Cape provinces and a lower
proportion having Zidovudine (ZDV) instead of Stavudine
included in the initial regimen. Baseline clinical status
variables were equivalent between the groups. Patients
supported by PAs had significantly fewer missing baseline
TB treatment values (2 [0.6%] vs. 276 [8.5%]; p B0.0005),
as well as fewer missing baseline immunological values
(44 [13.6%] vs. 766 [23.6%]; p B0.0005).
The total observation time was 4848 person-years, with
median observation times of 18.5 months per child (IQR: 8.4
Table 1. Baseline characteristics of ART-naı ¨ve children beginning antiretroviral therapy
All Children with PAs Children without PAs p
No. of children n (%) 3563 323 (9.1) 3240 (90.9)
Median age, y (IQR) 6.3 (3.3 to 9.5) 6.8 (3.2 to 9.8) 6.2 (3.3 to 9.5) 0.488
Age group categories, n (%) 0.043
B1 year 184 (5.2) 26 (8.1) 158 (4.9)
1 to 2 years 323 (9.1) 26 (8.1) 297 (9.1)
 2 years 3056 (85.8) 271 (83.9) 2785 (86.0)
Female, n (%) 1757 (49.3) 161 (49.9) 1596 (49.3) 0.841
WHO clinical stage, n (%)
a,( n2350) 0.175
I/II 939 (40.0) 77 (35.7) 862 (40.4)
III/IV 1411 (60.0) 139 (64.4) 1272 (59.6)
WAZ-score, median (IQR), (n2259) 1.43 (2.46 to 0.55) 1.28 (2.51 to 0.37) 1.44 (2.46 to 0.56) 0.106
WAZ-score B 3, n (%)
a 361 (15.6) 22 (11.7) 339 (16.4) 0.209
CD4 cell percentage; median (IQR),
(n1734)
12.0 (7.0 to 17.9) 11.0 (7.0 to 15.0) 12.0 (7.1 to 18.0) 0.178
Absolute CD4 cell count (cells/ml);
median (IQR), (n2256)
239 (66 to 547) 218 (81 to 457) 240 (64 to 565) 0.214
Severe immunodeficiency
a, n (%)
a,( n2753) 1914 (69.5) 201 (72.0) 1713 (69.2) 0.335
Tuberculosis, n (%)
b (n3285) 124 (3.8%) 16 (5.0%) 108 (3.6%) 0.231
Initial ART regimen, n (%)
b,( n3390)
NNRTI based 2633 (77.7)
c 262 (81.1) 2371 (77.3) 0.118
PI-based 665 (19.6)
c 55 (17.0) 610 (19.9) 0.218
Including d4t 3266 (96.3)
c 321 (99.4) 2945 (96.0) 0.002
Including ZDV 216 (6.3)
c 8 (2.5) 208 (6.8) 0.003
PHC based care, n (%) 1507 (42.3) 306 (94.7) 1201 (37.1) B0.0005
Year of starting ART, n (%) 0.072
2004/2005 204 (5.7) 26 (8.1) 178 (5.5)
2006/2007 1399 (39.3) 113 (35.0) 1286 (39.7)
2008/2009 1960 (55.0) 184 (57.0) 1776 (54.8)
Rural ART facility, n (%) 334 (9.4) 9 (2.8) 325 (10.0) B0.0005
Province, n (%) B0.0005
Western Cape 486 (23.7) 57 (17.6) 429 (13.3)
Eastern Cape 410 (11.5) 16 (5.0) 394 (12.2)
Kwazulu-Natal 2472 (69.4) 158 (48.9) 2314 (71.4)
Mpumalanga 195 (5.5) 92 (28.5) 103 (3.2)
PA, patient advocates; WHO, World Health Organization; IQR, interquartile range; WAZ, weight for age z-score; ART, antiretroviral treatment;
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; d4t, stavudine; ZDV, zidovudine; PHC, primary healthcare.
aSevere immunodeficiency was defined according to World Health Organization’s age-specific CD4 cell count and percentage criteria;
bProportion
of children with available results;
c92 children received d4t and ZDV and did not receive an NNRTI or a PI.
Grimwood A et al. Journal of the International AIDS Society 2012, 15:17381
http://www.jiasociety.org/content/15/2/17381 | http://dx.doi.org/10.7448/IAS.15.2.17381
4to 30.2) amongst children with PAs and 15.2 months per
child (IQR: 8.2 to 22.4) amongst children without PAs. Using
facility-level data, amongst children with and without PAs,
4 (1.2%) and 106 (3.3%) children were ascertained as having
died during the study period, respectively, and 16 (5.0%)
and 195 (6.0%) were LTFU, respectively. Patient retention
(I  attrition) after 3 years of ART in children with PAs was
91.5% (95% CI: 86.8% to 94.7%) vs. 85.6% (95% CI: 83.3% to
87.6%) amongst children without PAs (logrank p 0.027)
(Fig. 1). Amongst children aged below 2 years when starting
ART, retention after 3 years was 92.2% (95% CI: 76.7%
to 97.6%) vs. 74.2% (95% CI: 65.4% to 81.0%) in children
with and without PAs, respectively (p 0.053; n507; 52
[10.3%] PA-supported).
Cumulative mortality based on facility-held data after
three years of ART was 1.5% (95% CI: 0.5% to 4.1%) in
children with PAs vs. 4.7% (95% CI%: 3.6% to 6.2%) amongst
children without PAs (logrank p 0.032). Amongst all chil-
dren LTFU, 93 (44.0%) had valid civil identification numbers,
of whom 36 (38.7%) were registered as having died in the
national registry by November 2010. The estimates of
corrected mortality based on the weighted dataset after
3 years of ART were 3.7% (95% CI: 1.9% to 7.4%) amongst
children with PAs vs. 8.0% (95% CI: 6.5% to 9.8%) amongst
children without PAs (logrank p 0.060) (Fig. 2). Corrected
mortality rates on ART were 1.6 deaths per 100 child-years
(95% CI: 0.7 to 4.9) vs. 4.2 deaths per 100 child-years (95% CI:
3.5 to 5.1) in children with and without PAs, respectively
(p 0.060). Amongst children aged below 2 years when
starting ART, corrected mortality rates were 1.5 deaths per
100 child-years (95% CI: 0.5 to 10.5) vs. 7.7 deaths per 100
child-years (95% CI: 5.3 to 11.7) in children with and without
PAs, respectively (p0.12).
In multivariable analyzes adjusting for all available baseline
variables (Table 2), children with PAs had an independently
reduced probability of attrition, adjusted hazard ratio (AHR)
0.57 (95% CI: 0.35 to 0.94; p 0.026) and a reduced
probability of mortality (based on the weighted data), AHR
0.39 (95% CI: 0.15 to 1.04; p 0.060). Other baseline factors
independently associated with mortality were age under
2 years (AHR 1.70 [95% CI: 1.01 to 2.85]), WAZ-scores below
3 (AHR 3.95 [95% CI: 2.38 to 6.56]), severe immunodefi-
ciency (AHR 2.36 [95% CI: 1.27 to 4.64]) and receiving
treatment for TB (AHR 2.37 [95% CI: 1.21 to 4.64]). Mortality
was higher in KwaZulu-Natal and Mpumalanga provinces
compared with that of the Western Cape. Mortality and
attrition were equivalent between PHC and hospital facilities.
The improved outcomes in PA-supported children re-
mained apparent when sensitivity analyses were performed.
When death registry information was ignored and vital status
based on site-level ascertainment only, PA-supported chil-
dren had an independently reduced probability of death, AHR
0.26 (95% CI: 0.09 to 0.75; p 0.013, n3563). Analyses
limited to the sites at which PAs were active included 1577
(83.0%) patients who did not receive PA support. In multi-
variable models, attrition and corrected mortality were both
independently reduced in PA-supported children at these
sites; AHR 0.49 (95% CI: 0.28 to 0.87, p 0.015, n1900)
Figure 1. Kaplan-Meier estimates of retention in care for children with and without patient advocates. ART, antiretroviral therapy, PAs,
patient advocates; CI, confidence interval.
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5and AHR 0.24 (95% CI: 0.07 to 0.76, p 0.015, n1848),
respectively.
Analyses limited to the 32 PHC clinics included 1507
children, with 306 (20.3%) receiving PA support. After
36 months of ART, retention in care was 90.1% (95% CI:
85.9% to 94.3%) in patients with PAs vs. 80.0% (95% CI:
73.0% to 85.3%) in patients without PAs, respectively
(logrank p 0.036). In multivariable models, attrition and
corrected mortality were independently reduced in PA-
supported children, AHR 0.57 (95% CI: 0.34 to 0.97;
p 0.039) and AHR 0.37 (95% CI: 0.13 to 1.06; p 0.065),
respectively.
The proportion of patients achieving virological suppres-
sion was equivalent between children with and without PA
support. Virological suppression was 78.8% (95% CI: 71.7%
to 85.9%; n132) and 82.4% (95% CI: 80.4% to 84.4%;
n1409) (p 0.30) in children with and without PAs,
respectively, after 6 months of ART; and after 12 months it
was 80.6% (95% CI: 73.0% to 88.1%; n108) vs. 78.5% (95%
CI: 75.9% to 81.1%; n959) (p 0.62) in children with and
without PAs, respectively. Virological suppression was also
equivalent between PHC and hospital facilities (p 0.10
after 6 months; p 0.85 after 12 months).
Median CD4 percentage increases were equivalent be-
tween children with and without PA support; overall increases
were 8.0% (IQR: 4.0% to 12.7%; p 0.57; n972) after
six months and 11.1% (IQR: 6.8% to 17.1%; p 0.43; n652)
after 12 months of ART. Median CD4 percentage increases
were also equivalent between PHC and hospital facilities
(p 0.86 after 6 months; p 0.87 after 12 months).
Discussion
This study is amongst the first to evaluate the impact of a
multicentrecommunity-basedadherence-supportprogramme
for children receiving ART in sub-Saharan Africa and has
demonstrated an approximately 40% reduction in patient
attrition over 3 years of treatment. Mortality rates of children
with PAs were comparable with those of children on ART in
developed countries [7]. Community health workers form a
significant workforce in HIV programmes in South Africa [25]
and this data provides empirical evidence of their benefit for
children receiving ART, as has previously been demonstrated
for adults [18,20]. It contributes to possible solutions to the
poor paediatric survival on ART in LMIC [7], as well as
augments the existing body of data from non-ART settings
demonstrating the positive impact of community health
workers in improving child survival [14]. These results also
concur with previous studies showing that paediatric ARTcan
be successfully provided in a decentralized manner at PHC
facilities located within the community being served [26,27].
Infants are a particularly vulnerable group with increased
risk of death on ART due to immune system immaturity
[5,28]. PA-supported children had a higher proportion of
infants aged below one year when starting ART; nevertheless,
PA-supported children demonstrated lower overall mortality
on ART. In addition, although the sample was small, retention
Figure 2. Weighted Kaplan-Meier estimates of corrected mortality for children with and without patient advocates. For patients who were
lost to follow-up with available civil identification numbers, vital status was ascertained from the national death registry.These patients were
weighted in the analysis to represent all patients lost to follow-up. ART, antiretroviral therapy, PAs, patient advocates; CI, confidence interval.
Grimwood A et al. Journal of the International AIDS Society 2012, 15:17381
http://www.jiasociety.org/content/15/2/17381 | http://dx.doi.org/10.7448/IAS.15.2.17381
6amongst children aged below 2 years was particularly
improved in PA-supported children.
In addition to healthcare, PAs assist with access to vital
documentation and social income grants, as fewer than 70%
of eligible carers access child or foster care grants in South
Africa [29]. This is expected to improve the households’
economic status and reduce food insecurity, both of which
are associated with improved child survival [30,31]. PA-
supported children also had more recorded data on TB,
which may indicate an earlier awareness of potential health
problems and referral for appropriate interventions, leading
to improved survival.
The large numbers of missing viral loads amongst all
children is, however, of concern.This problem applies to both
adults and children at government facilities, is common to
ART programmes in sub-Saharan Africa and other LMIC
[27,32] and is due to a combination of testing being omitted,
misplacing of blood specimens, laboratory technical pro-
blems, non-retrieval of laboratory results and failure to enter
results in site databases timeously due to human resource
constraints. Attempts are currently underway to improve the
availability of viral load test results.
Community-based adherence-support expands the nexus
of interdependent factors needed to sustain adherence
and patient retention on ART [4,20]. Scaling-up community
interventions may significantly impact children’s treat-
ment outcomes and need to be considered as part of the
implementation and not as a substitute for the formal
health sector [25] of large-scale treatment initiatives as
the country ramps up to meet the United Nations vision
of zero AIDS-related deaths and zero new infections, in a
climate of zero discrimination by 2015 [33]. This strategy
should form part of clinical services provided at the PHC
level if South Africa is to achieve this goal. Formal cost-
effectiveness studies of this intervention should also be
conducted.
Strengths and limitations
The strengths of this study are that pooled data from a
large number of patients and sites in different settings
Table 2. Characteristics at the start of ART associated with mortality and attrition in multivariable Cox regression models
a.
Mortality (corrected)
b Attrition
c
Adjusted hazard
ratio
95% confidence
interval p value
Adjusted hazard
ratio
95% confidence
interval p value
Children with PAs 0.39 0.15 to 1.04 0.060 0.57 0.35 to 0.94 0.026
Male gender 0.96 0.68 to 1.34 0.94 0.92 0.76 to 1.12 0.46
Age category
] 2 years
d 1  1 
B2 years 1.70 1.01 to 2.85 0.048 1.64 1.17 to 2.29 0.007
WHO stage
III
d 1  1 
IIIIV 1.28 0.79 to 2.07 0.48 0.89 0.67 to 1.16 0.32
WAZ-score
 2
d 1  1 
3t o2 1.23 0.59 to 2.56 0.38 1.04 0.71 to 1.51 0.42
B3 3.95 2.38 to 6.56 B0.0005 2.74 1.95 to 3.84 B0.0005
Severe Immunodeficiency 2.36 1.27 to 4.39 0.001 1.20 0.89 to 1.62 0.34
Tuberculosis 2.37 1.21 to 4.64 0.006 1.40 0.79 to 2.49 0.21
Initial ART regimen
PI-based 0.88 0.53 to 1.47 0.78 1.07 0.80 to 1.44 0.67
d4t-based 0.59 0.20 to 1.72 0.45 0.91 0.55 to 1.51 0.60
PHC-based care 0.83 0.51 to 1.37 0.48 0.85 0.63 to 1.16 0.25
Rural ART facility 0.76 0.45 to 1.29 0.31
Province
Western Cape
d 1 
Eastern Cape 2.44 0.80 to 7.51 0.112 1.20 0.64 to 2.25 0.57
Kwazulu-Natal 3.53 1.43 to 8.70 0.006 1.40 0.83 to 2.32 0.20
Mpumalanga 3.85 1.20 to 12.32 0.023 1.63 0.81 to 3.23 0.17
ART, antiretroviral therapy; CI, confidence interval; PHC, primary healthcare; WAZ, weight for age z-score; WHO, World Health Organization;
d4T, stavudine.
aEstimates are adjusted for all variables in the table as well as year of starting ART. Children with missing baseline values were included in
analyses by adding a missing category to variables;
bWeighted analyses with corrected mortality, weighted n3445;
cn3563;
dReference
category.
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7were used, and prospective individual-level data were
collected enabling adjustment of patient factors associated
with outcomes. In addition, the vital status of patients
LTFU who had identification numbers was determined from
the national death registry, allowing corrected mortality
estimates to be derived.
This study analyzed routine data with its inherent
limitations; however, it is likely to be indicative of the
situation at the operational level. As PAs worked in the
geographic areas of the local clinics, children who did not
receive PAs at sites with the community-based programme
may have lived at greater distances from the clinic than
children who received PAs. This may have increased the
risk of LTFU in non-PA-supported children, which was not
able to be accounted for in the analysis as travel distance
does not form part of the routine data collected on public
sector ART patients. Adherence determination data were
not analyzed as there are no national standard government
protocols or tools to measure patient-level adherence.
Baseline socio-economic factors may be associated with
mortality, but this variable could not be included in
analyzes as it was not possible to collect socio-economic
data for the whole cohort. However, previous analyzes in
adults showed that patients from lower socio-economic
strata at baseline were more likely to be attached to a PA
[18]; therefore, this factor is unlikely to have confounded
effect measures in favour of PA support. All the sites were
supported by an NGO, and it is possible that the outcomes
may not be well generalizable to non-NGO-supported
government health facilities. Data on maternal character-
istics, which may be a potential confounder of outcomes,
were not available for analysis.
Conclusion
This study indicates that community-based adherence
support is an effective way to improve patient retention
amongst children receiving ART in a low-income setting. As
more children start accessing ART as South Africa scales-up
programmes to meet its treatment needs, support for the
carers of these children is critical to maintain patient
retention. Future randomized studies should be undertaken
which include larger samples of children receiving commu-
nity-based support that include measurement of adher-
ence, psychosocial barriers to adherence and clinic travel
distance. In the absence of these, however, large-scale
implementation of this low-cost, useful intervention should
be considered as part of collective practical interventions
by health authorities [12,34] embarking on the ambitious
programme to see every HIV-positive child under 1 year
of age access ART and almost all PHC facilities initiate
paediatric treatment across South Africa. The provision of
ward-based community healthcare workers is one of the
three critical interventions envisaged by the National
Department of Health’s Re-engineering of PHC strategy
for improving health outcomes [35]. The PA programme
has much valuable learning that could further inform and
refine this strategy.
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